The international consortium on lithium genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment

Thomas G. Schulze, Martin Alda, Mazda Adli, Nirmala Akula, Raffaella Ardau, Elise T. Bui, Caterina Chillotti, Sven Cichon, Piotr Czerski, Maria Del Zompo, Sevilla D. Detera-Wadleigh, Paul Grof, Oliver Gruber, Ryota Hashimoto, Joanna Hauser, Rebecca Hoban, Nakao Iwata, Layla Kassem, Tadafumi Kato, Sarah Kittel-SchneiderSebastian Kliwicki, John R. Kelsoe, Ichiro Kusumi, Gonzalo Laje, Susan G. Leckband, Mirko Manchia, Glenda MacQueen, Takuya Masui, Norio Ozaki, Roy H. Perlis, Andrea Pfennig, Paola Piccardi, Sara Richardson, Guy Rouleau, Andreas Reif, Janusz K. Rybakowski, Johanna Sasse, Johannes Schumacher, Giovanni Severino, Jordan W. Smoller, Alessio Squassina, Gustavo Turecki, L. Trevor Young, Takeo Yoshikawa, Michael Bauer, Francis J. McMahon

研究成果: Review article

89 引用 (Scopus)

抜粋

For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.

元の言語English
ページ(範囲)72-78
ページ数7
ジャーナルNeuropsychobiology
62
発行部数1
DOI
出版物ステータスPublished - 06-2010

All Science Journal Classification (ASJC) codes

  • Neuropsychology and Physiological Psychology
  • Psychiatry and Mental health
  • Biological Psychiatry

フィンガープリント The international consortium on lithium genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Schulze, T. G., Alda, M., Adli, M., Akula, N., Ardau, R., Bui, E. T., Chillotti, C., Cichon, S., Czerski, P., Del Zompo, M., Detera-Wadleigh, S. D., Grof, P., Gruber, O., Hashimoto, R., Hauser, J., Hoban, R., Iwata, N., Kassem, L., Kato, T., ... McMahon, F. J. (2010). The international consortium on lithium genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology, 62(1), 72-78. https://doi.org/10.1159/000314708